Johnson & Johnson

The global atrial fibrillation treatment devices market is projected to grow from USD 9.6 billion in 2026 to USD 29.0 billion by 2035, at a compound annual growth rate of 13.1%, according to a new report from ResearchAndMarkets.com. The market expansion is driven by the rising prevalence of atrial fibrillation, an aging population, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Ablation catheters are expected to account for approximately 75% of market revenue, while the left atrial appendage closure segment is projected to grow at a CAGR of 13.4%, the fastest among device types. Pulsed field ablation is forecast to generate more than 60% of total market revenue by 2035. North America is projected to retain close to 50% of global revenue, while Asia-Pacific is expected to register the fastest regional growth. Key players include Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic.

Johnson & Johnson announced that the FDA has approved Imaavy, also known as nipocalimab-aahu, for the treatment of warm autoimmune hemolytic anemia in adults and pediatric patients aged 12 years and above who are currently or have been previously treated with corticosteroids. The approval makes Imaavy the first FDA-approved treatment specifically indicated for wAIHA, a rare and potentially life-threatening autoimmune disease in which autoantibodies attack and destroy red blood cells, resulting in severe anemia and debilitating fatigue. The approval was based on data from the pivotal phase II/III ENERGY study, which showed that patients receiving the approved 30 mg/kg dose achieved a significantly higher rate of durable hemoglobin response compared with placebo, with approximately three times as many patients achieving durable hemoglobin levels by week 24. Imaavy also demonstrated a rapid treatment effect, with a mean hemoglobin increase of 1 g/dL as early as week 1, and patients treated with Imaavy showed a 3.5-point greater mean improvement in FACIT-Fatigue scores at week 24 compared with placebo. The latest approval marks an important milestone for J&J's immunology portfolio and provides Imaavy with an additional commercial opportunity beyond its existing use in generalized myasthenia gravis, for which it was approved in April 2025 in the U.S. and in December 2025 in the EU.

Dick's Sporting Goods shares fell 18.23% in premarket trading Tuesday after the retailer missed quarterly estimates and issued a cautious full-year outlook amid a promotional sporting goods backdrop. Comparable sales rose 4.9%, helped by broad-based category growth including strong results from the 2026 FIFA World Cup, while Foot Locker's pro forma comparable sales fell 3.6%. Meta Platforms gained 0.66% premarket on a report that it plans to launch a consumer-facing AI agent in the coming weeks and a new AI model in October. Johnson & Johnson rose 0.49% after the FDA approved a label expansion for its myasthenia gravis therapy Imaavy as a treatment for warm autoimmune hemolytic anemia, potentially making it the first U.S.-approved therapy for wAIHA. Hims & Hers Health edged up 0.26% premarket after tumbling over 8% Monday on reports that Visa will impose nearly $75,000 in penalties in September after thousands of credit card dispute complaints tied to weight-loss subscriptions triggered its inclusion in Visa's Acquirer Monitoring Program.

Apple, EMCOR Group, and Johnson & Johnson each reported record-breaking results in their latest quarterly reports. Apple posted its strongest June-quarter ever with revenue of $109.4 billion, up 16% year-over-year, and adjusted EPS of $2.02, up 29%. EMCOR Group delivered record revenues of $5.2 billion, up nearly 20%, and adjusted EPS of $9.06, up 35%, while also reporting record remaining performance obligations of $17.1 billion. Johnson & Johnson achieved a new quarterly sales record of $25.3 billion, up 6.6%, and raised its full-year guidance, putting it on track to surpass $100 billion in annual revenue for the first time.

Johnson & Johnson's pipeline is becoming an increasingly important growth driver as the company looks to offset future pressure from mature products such as Stelara and eventually Darzalex. The company has a particularly strong set of catalysts in oncology, immunology and neuroscience, with several potential approvals, label expansions and important phase III readouts scheduled. In the past year, it has gained approval for new products like Inlexzo/TAR-200, a first-of-its-kind drug-releasing system, for treating high-risk non-muscle invasive bladder cancer, Imaavy (nipocalimab) for treating generalized myasthenia gravis and Icotyde (icotrokinra), an oral targeted peptide inhibitor of the IL-23 receptor, for treating moderate-to-severe plaque psoriasis. J&J markets Icotyde in partnership with Protagonist Therapeutics. On the second-quarter conference call, J&J said that it is seeing strong launches of Inlexzo, Icotyde, as well as Imaavy. Nipocalimab, an FcRn blocker, is also being evaluated for various immune-mediated conditions. It is under priority review in the United States for warm autoimmune hemolytic anemia, in late-stage studies for hemolytic disease of the fetus and newborn, systemic lupus erythematosus and Sjogren's disease, and in mid-stage studies for idiopathic inflammatory myopathy. J&J believes that nipocalimab has pipeline-in-a-product potential. J&J believes that Icotyde/icotrokinra has the potential to revolutionize the treatment of plaque psoriasis with a once-daily pill, whereas most currently available effective options for treating plaque psoriasis are injectables, such as AbbVie's popular injection, Skyrizi, and J&J's own injection, Tremfya. Icotyde offers a compelling advantage over existing plaque psoriasis treatments by combining biologic-level precision with the convenience of an oral pill. Unlike injectable IL-23 biologics, such as AbbVie's Skyrizi and Tremfya, it eliminates the need for injections, improving patient comfort and adherence. Icotrokinra is also being evaluated in phase III studies for ulcerative colitis and psoriatic arthritis and in phase II for Crohn's Disease. It has the potential to be J&J's largest product ever, with $10 billion in sales potential. J&J expects several meaningful pipeline catalysts in the second half of the year, including potential FDA regulatory approval for Imaavy for warm autoimmune hemolytic anemia. In July, J&J announced positive top-line data from the phase III MonumenTAL-6 study evaluating Tecvayli plus Talvey in patients with relapsed or refractory multiple myeloma who had received one to four prior lines of therapy. The combination regimen reduced the risk of disease progression or death by 89% versus investigator's choice of standard care while reducing the risk of death by 62%. Other important data readouts expected later this year include Inlexzo in high-risk bladder cancer, Icotyde in psoriatic arthritis and Caplyta in bipolar mania. A key pipeline candidate is JNJ-4804, a co-antibody therapeutic being developed in phase III studies for ulcerative colitis and Crohn's disease. The company is also working on expanding labels of currently marketed products like Darzalex, Tremfya, Carvykti, Erleada, Rybrevant/Lazcluze and others. As regards its MedTech segment, a key product approved recently in the United States was the OTTAVA robotic surgery system, J&J's next-generation soft-tissue surgical robot. It was approved in July. VARIPULSE Pro, an advanced Pulsed Field Ablation platform, is expected to be approved by the FDA later this year. VARIPULSE Pro was launched in the EU in April. Overall, J&J's robust pipeline and a steady stream of clinical and regulatory catalysts should support growth in the second half of 2026 and beyond. The potential expansion of newer drugs, strong late-stage candidates and continued MedTech innovation provide multiple avenues for J&J to offset patent pressures and sustain long-term growth. J&J's shares have outperformed the industry so far this year. The stock has risen 30.6% year to date compared with 18.2% appreciation of the industry. From a valuation standpoint, J&J is expensive. Going by the price/earnings ratio, the company's shares currently trade at 21.84 forward earnings, higher than 19.50 for the industry. The stock is also trading above its five-year mean of 15.65. The Zacks Consensus Estimate for 2026 earnings has risen from $11.58 per share to $11.59 per share over the past 60 days, while that for 2027 earnings has gone up from $12.65 per share to $12.80 over the same time frame. J&J has a Zacks Rank #3 (Hold) at present.

Johnson & Johnson appears better prepared for its patent cliff than Pfizer, based on their latest results. J&J's Innovative Medicine sales rose 7.8% to $16.38 billion despite a 55% decline in Stelara revenue, helped by Tremfya sales jumping 72.5% to about $2 billion. The company raised its 2026 reported-sales guidance to a midpoint of $101.1 billion and increased adjusted EPS guidance by $0.13 to $11.68. Pfizer's revenue excluding Comirnaty and Paxlovid grew 5% operationally in fiscal Q2 2026, but total operational growth was only 1%, and the company recorded a GAAP net loss of $248 million. Pfizer expects about $9.7 billion in total net savings through 2029 from cost-realignment and manufacturing-optimization programs.

Johnson & Johnson has proposed a $5.5 billion settlement to resolve roughly 76,000 lawsuits alleging its talc products cause ovarian cancer. The agreement requires participation from at least 95% of eligible claimants, does not cover future lawsuits, and could ultimately cost more than the headline figure, with an attorney telling Reuters the payout could reach $7 billion or more. The company ended fiscal Q2 2026 with about $21 billion in cash and marketable securities and expects to pay up to $3 billion in 2027, followed by additional payments beginning in 2028. A federal judge has cast doubt on individual plaintiffs' ability to prove talc caused their cancer, suggesting J&J is settling from a position of improved legal strength. The settlement would reduce a major legal overhang but not eliminate talc liability entirely.

Johnson & Johnson and Thermo Fisher Scientific both reported encouraging quarterly results, with J&J raising its full-year sales and adjusted earnings guidance while Thermo Fisher saw a recovery in its Analytical Instruments segment. J&J's pharmaceutical business generated $16.38 billion in quarterly sales, exceeding analysts' estimate of $16.1 billion, and the company now expects annual sales of about $101.1 billion at the midpoint, up from $100.8 billion previously, with adjusted earnings per share forecast raised to $11.68 from $11.55. Thermo Fisher's Life Sciences Solutions segment reported revenue up 13% year over year, with organic revenue up 3%, led by strength in bioproduction, and its Analytical Instruments business returned to growth after nearly two years of weak demand. J&J's MedTech segment slightly missed expectations due to temporary headwinds including inventory pressures in China and softer U.S. procedure trends, while Thermo Fisher's organic revenue growth of 5% remains below its historical double-digit rates.

Johnson & Johnson received FDA 510(k) clearance for MONARCH QUEST 3, the latest software update for its MONARCH Platform for robotically assisted bronchoscopy. The update advances planning, navigation and targeting capabilities, with a focus on supporting clinicians during complex procedures and improving confidence in the early detection of lung cancer. The MONARCH Platform is the first flexible, robotically assisted bronchoscopy platform and provides continuous visualization throughout procedures, including navigation to and biopsy of targets under direct vision. MONARCH QUEST 3 builds on this foundation by enhancing the platform's ability to account for CT-to-body divergence and anatomical changes that may occur during bronchoscopy. The latest release incorporates Polyphonic for MONARCH, Johnson & Johnson's open digital ecosystem, which enables clinicians to review procedural volume data and collaborate through a centralized video library.

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval is based on Phase 3 MajesTEC-3 data showing the combination reduced the risk of disease progression or death by 83.4% compared to standard of care, with a hazard ratio of 0.17 and a p-value less than 0.001. Overall survival also favored the combination, with a hazard ratio of 0.46 and three-year overall survival rates of 83.3% versus 65.0% for standard of care. More than 90% of patients who were progression-free at six months remained progression-free at three years. The safety profile was consistent with the known profiles of the individual therapies, with all cytokine release syndrome cases being Grade 1 or 2 and no new safety signals identified.

Johnson & Johnson raised its quarterly dividend by 3.1% to $1.34 per share, marking the company's 64th consecutive year of dividend increases. The healthcare giant reported second-quarter 2026 revenue of $25.3 billion, up 6.6% year over year, with adjusted EPS climbing 4.7% to $2.90 and free cash flow jumping to about $8.7 billion from $6.2 billion a year earlier. Management also raised its full-year outlook to approximately $101.1 billion in sales and adjusted EPS of $11.68, implying a payout ratio of roughly 46%. The company highlighted FDA approval of ICOTYDE, an oral peptide for plaque psoriasis and the first targeted oral peptide of its kind, as part of a pipeline that supports future dividend growth.

Johnson & Johnson shares surged approximately 3% to $270.19 Tuesday morning as investors rotated out of high-growth technology stocks and into defensive companies. The healthcare heavyweight reported second-quarter sales climbed 6.6% to $25.31 billion, while adjusted earnings reached $2.90 per share. Management also raised its 2026 outlook, targeting approximately $101.1 billion in revenue and $11.68 in adjusted earnings per share at the midpoint. The stock is trading at $271.19 versus an estimated fair value of $192.38, meaning it sits roughly 41% above its GF Value.

Johnson & Johnson's immunology and neuroscience franchises are becoming meaningful growth engines as the company diversifies beyond oncology. In the first half of 2026, immunology contributed around 23% of Innovative Medicine sales with $7.22 billion in revenue, down 8.1% year over year due to Stelara's loss of exclusivity, while neuroscience accounted for approximately 14% with $4.5 billion in sales, up 20.5%. Tremfya sales surged 67.8% to $3.65 billion, and J&J expects it to exceed $10 billion in peak-year sales, while new launches Icotyde and Imaavy are seeing strong starts. Spravato sales rose 42% to $1.05 billion, and Caplyta generated $631 million following its November 2025 FDA approval for adjunctive major depressive disorder. J&J shares have risen 26.8% year to date, and the Zacks Consensus Estimate for 2026 earnings has edged up to $11.59 per share.

Johnson & Johnson raised its full-year 2026 guidance after second-quarter earnings and sales beat estimates. Adjusted earnings per share came in at $2.90, above the Zacks Consensus Estimate of $2.84, while sales of $25.3 billion edged past the $25.1 billion consensus. The company now expects 2026 reported sales of $100.8 billion to $101.4 billion, up from $100.3 billion to $101.3 billion, and adjusted EPS of $11.60 to $11.75, up from $11.45 to $11.65. Innovative Medicine sales rose 7.8% to $16.38 billion, driven by Darzalex, Tremfya, and new drugs like Carvykti, while MedTech sales increased 4.5% to $8.93 billion. Shares have added about 4.8% since the last earnings report, outperforming the S&P 500.

OmniAb reported second quarter 2026 revenue of $13.4 million and raised its full-year revenue guidance to a range of $32 million to $36 million, up from the prior $28 million to $33 million. The company's net loss narrowed to $5.9 million, or $0.05 per share, from $15.9 million a year earlier. OmniAb ended the quarter with 110 active partners and 425 active programs, including new license agreements with argenx and EnRosa Therapeutics. Management highlighted two programs that advanced directly from Phase I to Phase III during the quarter: J&J's Ramantamig and Merck KGaA's precemtabart tocentecan. The company also sold two xPloration instruments, bringing the total in the field to four, and expects year-end cash of $37 million to $41 million.

Johnson & Johnson has agreed to pay $5.5 billion to settle lawsuits alleging that its talc-based products caused ovarian cancer, covering nearly 80,000 outstanding claims. The proposed settlement requires support from 95% of eligible claimants to become effective, and previous settlement plans have fallen through. A federal judge recently questioned key expert testimonies linking talc to individual cancer cases and disqualified one plaintiffs' law firm, tilting things in the company's favor. If finalized, the settlement could reduce legal uncertainty that has weighed on Johnson's shares and management attention for years. Hedge fund interest in Johnson & Johnson rose to 113 funds at the end of Q1 2026, up from 104 in the previous quarter, with Fisher Asset Management boosting its position by 5% to $2.26 billion.

Johnson & Johnson is advancing its novel antidepressant Seltorexant into late-stage clinical development for major depressive disorder as a potential rapid-acting treatment option. The company also entered a multi-year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher-growth therapeutic and medtech areas that are important for its long-term outlook.

Legend Biotech Corporation reported a second-quarter profit of $33.2 million, or $0.09 per share, swinging from a loss of $125.4 million a year earlier, driven by a 50% surge in CARVYKTI sales to $657 million. Total revenue climbed 52% to $387.5 million, with collaboration revenue from the Johnson & Johnson partnership reaching $326.1 million. The company also highlighted positive clinical updates for pipeline programs LB2501 and LB2102, and ended the quarter with $965 million in cash, which it expects to fund operations beyond 2026.

Legend Biotech shares rose 6% after the company reported second-quarter 2026 results that beat estimates and delivered its first quarter of company-wide profitability. Total revenue reached $387.5 million, up 52% year over year and above the $362.81 million consensus, while adjusted earnings per share of $0.16 more than doubled the roughly $0.07 analyst forecast. CARVYKTI net trade sales hit $657 million, a 50% increase, and management reiterated peak annual sales potential above $5 billion for the CAR-T therapy co-developed with Johnson & Johnson's Janssen unit. The company also reported a pipeline milestone with first clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, showing a 100% overall response rate at the higher dose level. Interim CEO Alan Bash emphasized continuity following the departure of former CEO Ying Huang, while the Wall Street consensus price target of $52.10 remains well above current levels.

Johnson & Johnson received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system and advanced a US$5.50 billion talc settlement framework, reshaping its investment narrative. The company also reported strong Q2 2026 results, gained FDA Priority Review for its RYBREVANT FASPRO oncology franchise, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. These developments, alongside leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, highlight a strategic pivot toward higher-growth innovative medicines and medical technologies while addressing legacy legal exposures. The company's narrative projects $120.5 billion revenue and $28.6 billion earnings by 2029, requiring 7.2% yearly revenue growth and a $7.6 billion earnings increase from $21.0 billion today.

Johnson & Johnson has received FDA De Novo authorization for its OTTAVA robotic surgical system, marking its official entry into the U.S. soft-tissue robotic surgery market. The system features a table-integrated design that occupies 30% to 50% less space than traditional systems, and is authorized for multiple upper-abdominal general surgery procedures including gastric bypass, gastrectomy, cholecystectomy, gastric sleeve surgery, appendectomy, and hiatal hernia repair. Johnson & Johnson will begin a selective commercial launch with select U.S. customers, while also advancing the technology into additional regulatory jurisdictions and indications, with an ongoing clinical trial for inguinal hernia procedures. The company enters a market dominated by Intuitive Surgical, which had an installed base of 11,710 da Vinci systems at the end of the second quarter of 2026 and reported $2.89 billion in revenue for the quarter, up 19% year-over-year.

ACCESS, through its physician-led group purchasing organization ACCESS GPO, announced a multi-year preferred portfolio agreement with Johnson & Johnson to support the adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers across the United States. The agreement encompasses an integrated portfolio of three-dimensional mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies, including the CARTO System. The collaboration aims to help ASCs expand access to state-of-the-art therapies for cardiac arrhythmias while supporting the evolution of outpatient electrophysiology care. ACCESS GPO was established to support physician-led ASCs by improving access to advanced technologies and strengthening procedural economics.

Genmab raised its full-year revenue outlook to between $4.325 billion and $4.525 billion after first-half revenue climbed 25% to $2.05 billion, driven by a 24% increase in royalty revenue to $1.71 billion. The biotechnology company's U.S.-listed shares rose about 4.4% in Friday morning trading. Royalties from Johnson & Johnson's Darzalex, which generated $8.17 billion in sales, and Novartis' Kesimpta fueled the growth, while EPKINLY and TEPKINLY revenue surged 48% to $312 million. Adjusted operating profit rose 18% to $656 million, but reported operating profit edged up just 1% to $555 million due to integration costs and higher amortization. Management also lifted adjusted operating-profit guidance to $1.225 billion, even as operating expenses climb to support the launch of Rina-S and petosemtamab.

Royalty Pharma raised its full-year 2026 guidance for the second consecutive quarter, now expecting portfolio receipts of $3.4 billion to $3.5 billion and royalty receipts growth of 7% to 10%. Portfolio receipts grew 6% in the second quarter to $773 million, while total receipts rose 14%, driven by strong performances from Tremfya, Voranigo, Emdeltra, and Evrysdi. The company reported a return on invested capital of 14.2% and return on invested equity of 20.1% over the last twelve months. Capital deployment reached $349 million in the quarter, primarily for royalty funding for daraxonrasib and research and development funding for Johnson & Johnson's 4804 and litufilimab. Royalty Pharma also highlighted the acquisition of a 3.75% royalty on AstraZeneca's cliramitug, a potential blockbuster for ATTR-CM, with peak annual royalty potential of $110 million to $190 million.

A growing number of companies are raising their profit outlooks despite macroeconomic uncertainty. More S&P 500 firms are lifting guidance than cutting it, and Wall Street analysts have raised third-quarter earnings estimates for the index for the second consecutive quarter. Argus research analyst Christine Dooley views consistent guidance raises as a catalyst for market-beating returns. Among the companies that have raised guidance in the second quarter so far are Cheesecake Factory, Ford, General Motors, Hasbro, Starbucks, Coca-Cola, Charles Schwab, PayPal, US Bancorp, ASML, Seagate Technology, Supermicro Computer, Bristol Myers Squibb, Johnson & Johnson, UnitedHealth Group, 3M, Lockheed Martin, Northrop Grumman, United Airlines, and United Parcel Service.

Jim Cramer highlighted the FDA's De Novo marketing authorization for Johnson & Johnson's OTTAVA Robotic Surgical System as the catalyst that forced investors to recognize the healthcare giant as a high-tech innovator. The approval, announced on July 22, 2026, covers a range of general upper-abdominal procedures and marks the world's first table-integrated soft-tissue robotic platform. Cramer had been urging investors to accumulate JNJ stock after a strong earnings report that Wall Street initially dismissed, and the OTTAVA news sent the stock surging. He views holding JNJ as a portfolio 'permit' that allows investors to safely own aggressive tech growth while protecting against market pullbacks. Institutional holders control roughly 77% of JNJ shares, with 113 hedge funds holding positions in Q1 2026, and short interest remains minimal at 1.14%.

Johnson & Johnson reported a 16.1% operational increase in oncology revenue to $7.4 billion in the second quarter of 2026, driven by strong sales of Darzalex and Erleada. Darzalex sales grew nearly 18% to more than $4 billion, while Erleada rose 9.5% to $995 million, though Imbruvica declined 18.6% to $599 million due to U.S. competitive pressure. Newer cancer drugs Carvykti, Tecvayli, Talvey, and Rybrevant/Lazcluze together generated $1.38 billion, and newly launched Inlexzo saw sales more than double sequentially from about $30 million in the first quarter. Oncology now accounts for nearly 29% of total company revenues and about 45% of Innovative Medicine sales, and J&J aims to become the top oncology company by 2030 with projected sales exceeding $50 billion.

The dementia-related psychosis market across the seven major markets is forecast to expand at a compound annual growth rate of 26.2% from 2026 to 2036, according to a new report from DelveInsight. The market was valued at 690 million US dollars in 2025, with the United States accounting for approximately 77% of that total. More than 5 million diagnosed prevalent cases were reported across the seven major markets in 2025, including over 2 million in the US, where Alzheimer's disease dementia represented the largest share. Key therapies in development include ACP-204 from Acadia Pharmaceuticals, COBENFY from Bristol Myers Squibb, Zervimesine from Cognition Therapeutics, ML-007C-MA from Maplight Therapeutics, ITI-1284 from Johnson & Johnson, and low-dose levetiracetam from AgeneBio.

Bristol-Myers Squibb lifted its full-year outlook after reporting better-than-expected second-quarter 2026 results driven by higher sales of its cancer therapies. The company posted approximately $13.0 billion in revenue, beating consensus by $1.23 billion, with its growth portfolio contributing $7.6 billion. Adjusted earnings per share rose about 40% year-over-year to $2.04, exceeding estimates by $0.44. Bristol-Myers now expects full-year revenue of about $49.0 billion to $50.0 billion and adjusted EPS of $6.75 to $7.00, up from prior guidance and ahead of consensus. In other healthcare news, Johnson & Johnson agreed to pay up to $5.5 billion to settle remaining talc lawsuits alleging its products caused ovarian cancer, conditioned on at least 95% participation by claimants. Curium is in advanced talks to acquire Lantheus Holdings for about $7 billion upfront, with an additional $12.50 per share in contingent value rights, potentially valuing the deal at $8 billion. Boston Scientific shares slipped after its full-year outlook trailed consensus, despite second-quarter revenue of $5.4 billion beating estimates. Most Medicare Part D enrollees will face higher premiums in 2027 after the Trump administration ended a subsidy program, with three out of four seeing increases. The S&P 500 Health Care Index Sector edged up 0.12% during the week.

Johnson & Johnson's fair value estimate has been raised from $252.87 to $270.59 per share following a wave of analyst target increases. Several firms, including Scotiabank, TD Cowen, Citi, HSBC, Morgan Stanley, Goldman Sachs, Argus, RBC, and Guggenheim, have lifted their price targets into a range of roughly $260 to $305, citing solid Q2 results, updated guidance, and strength in new medicines such as Tremfya, Spravato, Caplyta, and Rybrevant. The company also proposed a settlement of up to $5.5 billion to resolve about 76,000 ovarian cancer talc lawsuits, contingent on 95% claimant acceptance, and reported positive Phase 3 results for TECVAYLI and TALVEY combinations in multiple myeloma, with the combination arm reducing the risk of disease progression or death by 89%. Additionally, Johnson & Johnson agreed to collaborate with Sail Biomedicines on in vivo CAR T therapies, involving initial payments of $785 million and an exclusive option to acquire Sail for $2.58 billion. The updated valuation reflects higher revenue growth assumptions of 7.17%, a net profit margin of 23.71%, and a future P/E of 28.08x, while the discount rate remained near 7.11%.

Johnson & Johnson raised its full-year guidance after second-quarter sales grew nearly 7% to $25.31 billion, beating the $25.05 billion estimate, while Danaher cut the upper end of its core revenue growth outlook range to 4% from 6% following a quarter that BofA called messier than expected. Johnson & Johnson's pharmaceutical unit generated $16.38 billion in quarterly sales, exceeding the $16.1 billion estimate, as a 72.5% surge in Tremfya sales to $2 billion helped offset a more than 55% drop in Stelara revenue to $740 million due to patent loss. The company now expects annual sales of about $101.1 billion at the midpoint and raised its adjusted earnings per share forecast to $11.68 from $11.55. Danaher's Life Sciences business delivered its strongest performance in several years, with bioprocessing orders growing mid-teens, but weaker-than-expected biotechnology revenue and a shift of a little over $100 million in revenue into next year weighed on results. Hedge fund ownership of Johnson & Johnson rose to 113 in the first quarter of 2026 from 104 in the prior quarter, while Danaher's fell to 110 from 125, according to Insider Monkey data.

Johnson & Johnson announced that the U.S. Food and Drug Administration has granted Priority Review to the supplemental Biologics License Application for subcutaneous amivantamab and hyaluronidase-lpuj, marketed as RYBREVANT FASPRO, for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. The Priority Review designation, which shortens the FDA review timeline to approximately six months, was supported by results from the pivotal Phase 1b/2 OrigAMI-4 study showing a 42 percent overall response rate, with more than one-third of responders achieving a complete response. Subcutaneous amivantamab is the only therapy in head and neck cancer engineered to target both EGFR and MET, which are overexpressed in 80 to 90 percent of these tumors and are proven drivers of tumor growth and treatment resistance. If approved, it would provide a new treatment option for patients facing a five-year survival rate of only 15 percent in the recurrent or metastatic setting. RYBREVANT FASPRO is already approved in more than 40 countries for non-small cell lung cancer and continues to be evaluated in additional tumor types.

Johnson & Johnson says it has reached a settlement worth at least $5.5 billion that could finally end over a decade of litigation alleging its talc products caused ovarian cancer. The deal requires acceptance from enough claimants to cover 95% of the estimated 76,000 ovarian cancer claims, a threshold that a plaintiffs' lawyer supporting the deal says could be met in a few months. Unlike J&J's three previous failed bankruptcy attempts, this settlement is voluntary, does not bind future claimants, and will pay claims in full in less than two years rather than over 25 years. J&J and leading plaintiffs' law firms have expressed confidence the deal will succeed, though some firms are still reviewing it. The settlement leaves J&J exposed to future lawsuits from people who may develop ovarian cancer later, given the disease's decades-long latency period.